# A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer

> **NCT05318573** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fujifilm Pharmaceuticals U.S.A., Inc.** · enrollment: 120 (estimated)

## Conditions studied

- Advanced Urothelial Carcinoma
- Advanced Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** FF-10832

## Key facts

- **NCT ID:** NCT05318573
- **Lead sponsor:** Fujifilm Pharmaceuticals U.S.A., Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-01
- **Primary completion:** 2029-05
- **Final completion:** 2029-11
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-09-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05318573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05318573, "A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05318573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*